UNITED THERAPEUTICS Corp (UTHR) stock
UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)
Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –
United Therapeutics total assets
Total assets on the balance sheet at the end of each period.
United Therapeutics's total assets was $7.22B at Jun 30, 2026. For fiscal 2025 it was $7.88B, up 7.0% from the year before. Over ten years it grew 13.7% a year on average. The highest annual figure on record is $7.88B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.88B | +7.0% |
| FY2024 | Dec 31, 2024 | $7.36B | +2.7% |
| FY2023 | Dec 31, 2023 | $7.17B | +18.6% |
| FY2022 | Dec 31, 2022 | $6.04B | +16.9% |
| FY2021 | Dec 31, 2021 | $5.17B | +12.0% |
| FY2020 | Dec 31, 2020 | $4.62B | +17.9% |
| FY2019 | Dec 31, 2019 | $3.91B | +15.1% |
| FY2018 | Dec 31, 2018 | $3.40B | +18.1% |
| FY2017 | Dec 31, 2017 | $2.88B | +23.8% |
| FY2016 | Dec 31, 2016 | $2.33B | +6.5% |
| FY2015 | Dec 31, 2015 | $2.18B | +15.9% |
| FY2014 | Dec 31, 2014 | $1.88B | -9.7% |
| FY2013 | Dec 31, 2013 | $2.09B | +28.3% |
| FY2012 | Dec 31, 2012 | $1.63B | +7.1% |
| FY2011 | Dec 31, 2011 | $1.52B | +6.0% |
| FY2010 | Dec 31, 2010 | $1.43B | +36.1% |
| FY2009 | Dec 31, 2009 | $1.05B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.22B | -8.7% |
| Q1 FY2026 | Mar 31, 2026 | $6.71B | -13.3% |
| Q4 FY2025 | Dec 31, 2025 | $7.88B | +7.0% |
| Q3 FY2025 | Sep 30, 2025 | $7.35B | +3.2% |
| Q2 FY2025 | Jun 30, 2025 | $7.91B | +17.6% |
| Q1 FY2025 | Mar 31, 2025 | $7.74B | +19.2% |
| Q4 FY2024 | Dec 31, 2024 | $7.36B | +2.7% |
| Q3 FY2024 | Sep 30, 2024 | $7.12B | +1.4% |
| Q2 FY2024 | Jun 30, 2024 | $6.72B | +0.6% |
| Q1 FY2024 | Mar 31, 2024 | $6.50B | +2.4% |
| Q4 FY2023 | Dec 31, 2023 | $7.17B | +18.6% |
| Q3 FY2023 | Sep 30, 2023 | $7.02B | +21.5% |
| Q2 FY2023 | Jun 30, 2023 | $6.68B | +20.5% |
| Q1 FY2023 | Mar 31, 2023 | $6.35B | +18.4% |
| Q4 FY2022 | Dec 31, 2022 | $6.04B | +16.9% |
| Q3 FY2022 | Sep 30, 2022 | $5.78B | +14.5% |
| Q2 FY2022 | Jun 30, 2022 | $5.54B | +14.4% |
| Q1 FY2022 | Mar 31, 2022 | $5.36B | +15.5% |
| Q4 FY2021 | Dec 31, 2021 | $5.17B | +12.0% |
| Q3 FY2021 | Sep 30, 2021 | $5.05B | +14.5% |
| Q2 FY2021 | Jun 30, 2021 | $4.84B | +14.8% |
| Q1 FY2021 | Mar 31, 2021 | $4.64B | +15.3% |
| Q4 FY2020 | Dec 31, 2020 | $4.62B | +17.9% |
| Q3 FY2020 | Sep 30, 2020 | $4.41B | +10.3% |
| Q2 FY2020 | Jun 30, 2020 | $4.22B | +8.2% |
| Q1 FY2020 | Mar 31, 2020 | $4.03B | +8.0% |
| Q4 FY2019 | Dec 31, 2019 | $3.91B | +15.1% |
| Q3 FY2019 | Sep 30, 2019 | $4.00B | +17.2% |
| Q2 FY2019 | Jun 30, 2019 | $3.90B | +20.2% |
| Q1 FY2019 | Mar 31, 2019 | $3.73B | +23.4% |
| Q4 FY2018 | Dec 31, 2018 | $3.40B | +18.1% |
| Q3 FY2018 | Sep 30, 2018 | $3.41B | +16.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.24B | +20.6% |
| Q1 FY2018 | Mar 31, 2018 | $3.02B | +17.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.88B | +23.8% |
| Q3 FY2017 | Sep 30, 2017 | $2.94B | +29.4% |
| Q2 FY2017 | Jun 30, 2017 | $2.69B | – |
| Q1 FY2017 | Mar 31, 2017 | $2.56B | – |
| Q4 FY2016 | Dec 31, 2016 | $2.33B | – |
| Q3 FY2016 | Sep 30, 2016 | $2.27B | – |
See a number that looks wrong?